Register Login
Register to leave comments
  • News bot Aug. 25, 2026, 8:57 p.m.

    📋 REGENXBIO INC. (RGNX) - Clinical Trial Update

    Filing Date: 2026-08-25

    Accepted: 2026-08-25 16:57:06

    Event Type: Clinical Trial Update

    Event Details:

    REGENXBIO INC. (RGNX) Announces Clinical Trial Update REGENXBIO INC. (RGNX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: experience, treatments
    • Diseases/Conditions: biotechnology investing
    • Collaboration: Board of Directors

    🔬 Clinical Development Pipeline (REGENXBIO INC.):

    Product Type Development Stage Therapeutic Area Source
    RGX-121-3102 Other Phase PHASE3 MPS II ClinicalTrials.gov
    RGX-111 Other Phase PHASE1 Mucopolysaccharidosis Type I (MPS I) ClinicalTrials.gov
    RGX-314 Other Phase PHASE1 Neovascular Age-related Macular Degeneration ClinicalTrials.gov
    ABBV-RGX-314 Dose 4 Other Phase PHASE2 Diabetic Retinopathy (DR) ClinicalTrials.gov
    RGX-202 Other Phase PHASE2 Duchenne Muscular Dystrophy ClinicalTrials.gov
    RGX-121 Other Phase PHASE1 Mucopolysaccharidosis Type II (MPS II) ClinicalTrials.gov
    Long-term Follow-Up Other Preclinical Mucopolysaccharidosis II ClinicalTrials.gov
    AAV8 DetectCDx Other Preclinical Duchenne Muscular Dystrophy ClinicalTrials.gov
    Observational Other Preclinical Mucopolysaccharidosis II ClinicalTrials.gov
    Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy Drug Preclinical Homozygous Familial Hypercholesterolemia (HoFH) ClinicalTrials.gov
    AAV directed hLDLR gene therapy Drug Phase PHASE1 Homozygous Familial Hypercholesterolemia (HoFH) ClinicalTrials.gov
    Aflibercept (2.0 mg) Other Phase PHASE2 Diabetic Macular Edema ClinicalTrials.gov
    RGX-314 Dose 2 Other Phase PHASE2 Diabetic Macular Edema ClinicalTrials.gov
    RGX-314 Dose 1 Other Phase PHASE2 Diabetic Macular Edema ClinicalTrials.gov
    Aflibercept Other Phase PHASE2 Diabetic Retinopathy (DR) ClinicalTrials.gov
    Topical Steroid Other Phase PHASE2 Diabetic Retinopathy (DR) ClinicalTrials.gov
    ABBV-RGX-314 Dose 3 Other Phase PHASE2 Diabetic Retinopathy (DR) ClinicalTrials.gov
    ABBV-RGX-314 Dose 2 Other Phase PHASE2 Diabetic Retinopathy (DR) ClinicalTrials.gov
    ABBV-RGX-314 Dose 1 Other Phase PHASE2 Diabetic Retinopathy (DR) ClinicalTrials.gov
    Local Steroid Other Phase PHASE2 Neovascular Age-Related Macular Degeneration (nAMD) ClinicalTrials.gov
    Ranibizumab Other Phase PHASE2 Neovascular Age-Related Macular Degeneration (nAMD) ClinicalTrials.gov
    No Intervention Other Preclinical Duchenne Muscular Dystrophy ClinicalTrials.gov
    Aflibercept (EYLEA®) Other Phase PHASE3 AMD ClinicalTrials.gov
    Ranibizumab (LUCENTIS®) Other Phase PHASE2 AMD ClinicalTrials.gov
    ABBV-RGX-314 Other Phase PHASE2 AMD ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: REGENXBIO INC.
    • Ticker Symbol: RGNX

Search

News categories